171-180 items (total 701)
Published on February 22, 2024
Discovery of a Mechanism Causing Drug Resistance in Breast Cancer: Metabolic Pathway Switching via Methylation of Multiple Glycolytic Enzymes Identified as a Key Factor—Paving the Way for New Therapeutic Targets Based on Metabolic Properties
Office of Communications and Public Relations
Published on February 21, 2024
"KEIO SPORTS SDGs Symposium 2024" to be Held on March 9-Beyond 2030: Considering New Value in Sports-
Office of Communications and Public Relations
Published on February 20, 2024
Evaluation of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Can Be Conducted via Online Consultations—Verifying the High Reliability of Remote ADHD Assessment—
Office of Communications and Public Relations
Published on February 19, 2024
Discovery of a New Fluorescence Quenching Mechanism Utilizing the Twisting of Rhodamine Fluorescent Dyes Commonly Used in Fluorescence Imaging—Hopes for the Development of New Fluorescent Probes
Office of Communications and Public Relations
Published on February 19, 2024
World's First Realization of Hybrid Transformer and CNN Processing with an Analog Compute-in-Memory Circuit—Achieving 10 Times Higher Computational Energy Efficiency than Conventional Methods and Reducing the Environmental Impact of AI—
Office of Communications and Public Relations
Published on February 16, 2024
The Impact of Student Loan Debt on Family Formation Among Young People: A Study Based on the "JHPS-G2"
Office of Communications and Public Relations
Published on February 14, 2024
2022 Change in Aggregation Method Found to Decrease Cases of Suicide with Unknown Reasons and Increase Cases with Identified Reasons—Offering New Insights into Understanding the Reasons for Modern Suicides
Office of Communications and Public Relations
Published on February 13, 2024
World's First Comprehensive Security Survey of LiDAR Sensors for Autonomous Driving—Discovering New Vulnerabilities and Paving the Way for Effective Defense Measures
Office of Communications and Public Relations
Published on February 09, 2024
Investigator-Initiated Clinical Trial Demonstrates Efficacy of Anti-PD-1 Antibody Therapy for Unresectable Advanced or Recurrent Epithelial Skin Cancer—Partial Change to Manufacturing and Marketing Approval Obtained in Japan for OPDIVO® Intravenous Infusion—
Office of Communications and Public Relations
Published on February 07, 2024
Comprehensive Genomic Analysis Identifies Genetic Factors Associated with Cold Sensitivity in Adult Women
Office of Communications and Public Relations